Expression of Circulating miR-21 and -29 and their Association with
Myocardial Fibrosis in Hypertrophic Cardiomyopathy

Andreas      Angelopoulos; Evangelos      Oikonomou; Alexios      Antonopoulos; Panagiotis      Theofilis; Konstantinos      Zisimos; Ourania      Katsarou; Maria      Gazouli; George      Lazaros; Paraskevi      Papanikolaou; Gerasimos      Siasos; Dimitris      Tousoulis; Konstantinos      Tsioufis; Charalambos      Vlachopoulos

doi:10.2174/0109298673286017240103073130

Abstract

Background: Hypertrophic Cardiomyopathy (HCM) is characterized by myocardial hypertrophy, fibrosis, and sarcomeric disarray.

Objective: To evaluate the expression levels of circulating miR-21 and -29 in patients with HCM and their association with clinical characteristics and myocardial fibrosis.

Methods: In this case-control study, 27 subjects with HCM, 13 subjects with hypertensive cardiomyopathy, and 10 control subjects were enrolled. Evaluation of patients’ functional capacity was made by the six-minute walk test. Echocardiographic measurements of left ventricle systolic and diastolic function were conducted. Cardiac magnetic resonance late gadolinium enhancement (LGE) -through a semiquantitative evaluation- was used in the assessment of myocardial fibrosis extent in HCM patients. The expression of miR-21 and -29 in peripheral blood samples of all patients was measured via the method of quantitative reverse transcription polymerase chain reaction.

Results: Circulating levels of miR-21 were higher in both hypertensive and HCM (p<0.001) compared to controls, while expression of miR-29 did not differ between the three studied groups. In patients with HCM and LGE-detected myocardial fibrosis in more than 4 out of 17 myocardial segments, delta CT miR-21 values were lower than in patients with myocardial LGE in 3 or fewer myocardial segments (2.71 ± 1.06 deltaCT vs. 3.50 ± 0.55 deltaCT, p<0.04), indicating the higher expression of circulating miR-21 in patients with more extensive myocardial fibrosis.

Conclusion: MiR-21 was overexpressed in patients with HCM and hypertensive cardiomyopathy. Importantly, in patients with HCM, more extensive myocardial fibrosis was associated with higher levels of miR-21.

« Previous Next »

[1]
Maron, B.J.; Ommen, S.R.; Semsarian, C.; Spirito, P.; Olivotto, I.; Maron, M.S. Hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.,  2014, 64(1), 83-99.
 [http://dx.doi.org/10.1016/j.jacc.2014.05.003] [PMID: 24998133]

[2]
Gersh, B.J.; Maron, B.J.; Bonow, R.O.; Dearani, J.A.; Fifer, M.A.; Link, M.S.; Naidu, S.S.; Nishimura, R.A.; Ommen, S.R.; Rakowski, H.; Seidman, C.E.; Towbin, J.A.; Udelson, J.E.; Yancy, C.W. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.,  2011, 58(25), e212-e260.
 [http://dx.doi.org/10.1016/j.jacc.2011.06.011] [PMID: 22075469]

[3]
Semsarian, C.; Ingles, J.; Maron, M.S.; Maron, B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.,  2015, 65(12), 1249-1254.
 [http://dx.doi.org/10.1016/j.jacc.2015.01.019] [PMID: 25814232]

[4]
Maron, B.J.; Maron, M.S. Hypertrophic cardiomyopathy. Lancet,  2013, 381(9862), 242-255.
 [http://dx.doi.org/10.1016/S0140-6736(12)60397-3] [PMID: 22874472]

[5]
Seidman, C.E.; Seidman, J.G. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history. Circ. Res.,  2011, 108(6), 743-750.
 [http://dx.doi.org/10.1161/CIRCRESAHA.110.223834] [PMID: 21415408]

[6]
Zile, M.R.; Brutsaert, D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation,  2002, 105(12), 1503-1508.
 [http://dx.doi.org/10.1161/hc1202.105290] [PMID: 11914262]

[7]
Sabbah, H.N.; Sharov, V.G.; Lesch, M.; Goldstein, S. Progression of heart failure: A role for interstitial fibrosis. Mol. Cell. Biochem.,  1995, 147(1-2), 29-34.
 [http://dx.doi.org/10.1007/BF00944780] [PMID: 7494551]

[8]
Varnava, A.M.; Elliott, P.M.; Sharma, S.; McKenna, W.J.; Davies, M.J. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Br. Heart J.,  2000, 84(5), 476-482.
 [http://dx.doi.org/10.1136/heart.84.5.476] [PMID: 11040002]

[9]
Gersh, B.J.; Maron, B.J.; Bonow, R.O.; Dearani, J.A.; Fifer, M.A.; Link, M.S.; Naidu, S.S.; Nishimura, R.A.; Ommen, S.R.; Rakowski, H.; Seidman, C.E.; Towbin, J.A.; Udelson, J.E.; Yancy, C.W. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J. Am. Coll. Cardiol.,  2011, 58(25), 2703-2738.
 [http://dx.doi.org/10.1016/j.jacc.2011.10.825] [PMID: 22075468]

[10]
Greaves, S.C.; Roche, A.H.; Neutze, J.M.; Whitlock, R.M.; Veale, A.M. Inheritance of hypertrophic cardiomyopathy: A cross sectional and M mode echocardiographic study of 50 families. Heart,  1987, 58(3), 259-266.
 [http://dx.doi.org/10.1136/hrt.58.3.259] [PMID: 3663427]

[11]
Barwari, T.; Joshi, A.; Mayr, M. MicroRNAs in cardiovascular disease. J. Am. Coll. Cardiol.,  2016, 68(23), 2577-2584.
 [http://dx.doi.org/10.1016/j.jacc.2016.09.945] [PMID: 27931616]

[12]
Shieh, J.T.C.; Huang, Y.; Gilmore, J.; Srivastava, D. Elevated miR-499 levels blunt the cardiac stress response. PLoS One,  2011, 6(5), e19481.
 [http://dx.doi.org/10.1371/journal.pone.0019481] [PMID: 21573063]

[13]
Fichtlscherer, S.; De Rosa, S.; Fox, H.; Schwietz, T.; Fischer, A.; Liebetrau, C.; Weber, M.; Hamm, C.W.; Röxe, T.; Müller-Ardogan, M.; Bonauer, A.; Zeiher, A.M.; Dimmeler, S. Circulating microRNAs in patients with coronary artery disease. Circ. Res.,  2010, 107(5), 677-684.
 [http://dx.doi.org/10.1161/CIRCRESAHA.109.215566] [PMID: 20595655]

[14]
Economou, E.K.; Oikonomou, E.; Siasos, G.; Papageorgiou, N.; Tsalamandris, S.; Mourouzis, K.; Papaioanou, S.; Tousoulis, D. The role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment. Atherosclerosis,  2015, 241(2), 624-633.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2015.06.037] [PMID: 26117399]

[15]
Latsios, G.; Tousoulis, D.; Androulakis, E.; Papageorgiou, N.; Synetos, A.; Toutouzas, K.; Siasos, G.; Oikonomou, E.; Stefanadis, C. MicroRNAs in the diagnosis and treatment of unstable angina. Curr. Top. Med. Chem.,  2013, 13(13), 1596-1604.
 [http://dx.doi.org/10.2174/15680266113139990108] [PMID: 23745811]

[16]
Briasoulis, A.; Sharma, S.; Telila, T.; Mallikethi-Reddy, S.; Papageorgiou, N.; Oikonomou, E.; Tousoulis, D. MicroRNAs in atrial fibrillation. Curr. Med. Chem.,  2019, 26(5), 855-863.
 [http://dx.doi.org/10.2174/0929867324666170920151024] [PMID: 28933293]

[17]
Moushi, A.; Michailidou, K.; Soteriou, M.; Cariolou, M.; Bashiardes, E. MicroRNAs as possible biomarkers for screening of aortic aneurysms: A systematic review and validation study. Biomarkers,  2018, 23(3), 253-264.
 [http://dx.doi.org/10.1080/1354750X.2018.1423704] [PMID: 29297231]

[18]
Moushi, A.; Pillar, N.; Keravnou, A.; Soteriou, M.; Shomron, N.; Cariolou, M.A.; Bashiardes, E. MicroRNAs in ascending thoracic aortic aneurysms. Biosci. Rep.,  2020, 40(7), BSR20200218.
 [http://dx.doi.org/10.1042/BSR20200218] [PMID: 32678444]

[19]
Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.; Shah, A.; Willeit, J.; Mayr, M. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res.,  2010, 107(6), 810-817.
 [http://dx.doi.org/10.1161/CIRCRESAHA.110.226357] [PMID: 20651284]

[20]
Briasoulis, A.; Tousoulis, D.; Vogiatzi, G.; Siasos, G.; Papageorgiou, N.; Oikonomou, E.; Genimata, V.; Konsola, T.; Stefanadis, C. MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus. Curr. Top. Med. Chem.,  2013, 13(13), 1533-1539.
 [http://dx.doi.org/10.2174/15680266113139990102] [PMID: 23745805]

[21]
Bagnall, R.D.; Tsoutsman, T.; Shephard, R.E.; Ritchie, W.; Semsarian, C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One,  2012, 7(9), e44744.
 [http://dx.doi.org/10.1371/journal.pone.0044744] [PMID: 23024758]

[22]
Roncarati, R.; Viviani Anselmi, C.; Losi, M.A.; Papa, L.; Cavarretta, E.; Da Costa Martins, P.; Contaldi, C.; Saccani Jotti, G.; Franzone, A.; Galastri, L.; Latronico, M.V.G.; Imbriaco, M.; Esposito, G.; De Windt, L.; Betocchi, S.; Condorelli, G. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol.,  2014, 63(9), 920-927.
 [http://dx.doi.org/10.1016/j.jacc.2013.09.041] [PMID: 24161319]

[23]
Zhou, J.; Zhou, Y.; Wang, C.X. LncRNA-MIAT regulates fibrosis in hypertrophic cardiomyopathy (HCM) by mediating the expression of miR-29a-3p. J. Cell. Biochem., 2018.
 [PMID: 30548303]

[24]
Fang, L.; Ellims, A.H.; Moore, X.; White, D.A.; Taylor, A.J.; Chin-Dusting, J.; Dart, A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med.,  2015, 13(1), 314.
 [http://dx.doi.org/10.1186/s12967-015-0672-0] [PMID: 26404540]

[25]
Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.E.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.E.; Shlyakhto, E.; Tsioufis, C.; Aboyans, V.; Desormais, I.; De Backer, G.; Heagerty, A.M.; Agewall, S.; Bochud, M.; Borghi, C.; Boutouyrie, P.; Brguljan, J.; Bueno, H.; Caiani, E.G.; Carlberg, B.; Chapman, N.; Cífková, R.; Cleland, J.G.F.; Collet, J-P.; Coman, I.M.; de Leeuw, P.W.; Delgado, V.; Dendale, P.; Diener, H-C.; Dorobantu, M.; Fagard, R.; Farsang, C.; Ferrini, M.; Graham, I.M.; Grassi, G.; Haller, H.; Hobbs, F.D.R.; Jelakovic, B.; Jennings, C.; Katus, H.A.; Kroon, A.A.; Leclercq, C.; Lovic, D.; Lurbe, E.; Manolis, A.J.; McDonagh, T.A.; Messerli, F.; Muiesan, M.L.; Nixdorff, U.; Olsen, M.H.; Parati, G.; Perk, J.; Piepoli, M.F.; Polonia, J.; Ponikowski, P.; Richter, D.J.; Rimoldi, S.F.; Roffi, M.; Sattar, N.; Seferovic, P.M.; Simpson, I.A.; Sousa-Uva, M.; Stanton, A.V.; van de Borne, P.; Vardas, P.; Volpe, M.; Wassmann, S.; Windecker, S.; Zamorano, J.L.; Windecker, S.; Aboyans, V.; Agewall, S.; Barbato, E.; Bueno, H.; Coca, A.; Collet, J-P.; Coman, I.M.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gaemperli, O.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Knuuti, J.; Lancellotti, P.; Leclercq, C.; McDonagh, T.A.; Piepoli, M.F.; Ponikowski, P.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Zamorano, J.L.; Tsioufis, C.; Lurbe, E.; Kreutz, R.; Bochud, M.; Rosei, E.A.; Jelakovic, B.; Azizi, M.; Januszewics, A.; Kahan, T.; Polonia, J.; van de Borne, P.; Williams, B.; Borghi, C.; Mancia, G.; Parati, G.; Clement, D.L.; Coca, A.; Manolis, A.; Lovic, D.; Benkhedda, S.; Zelveian, P.; Siostrzonek, P.; Najafov, R.; Pavlova, O.; De Pauw, M.; Dizdarevic-Hudic, L.; Raev, D.; Karpettas, N.; Linhart, A.; Olsen, M.H.; Shaker, A.F.; Viigimaa, M.; Metsärinne, K.; Vavlukis, M.; Halimi, J-M.; Pagava, Z.; Schunkert, H.; Thomopoulos, C.; Páll, D.; Andersen, K.; Shechter, M.; Mercuro, G.; Bajraktari, G.; Romanova, T.; Trušinskis, K.; Saade, G.A.; Sakalyte, G.; Noppe, S.; DeMarco, D.C.; Caraus, A.; Wittekoek, J.; Aksnes, T.A.; Jankowski, P.; Polonia, J.; Vinereanu, D.; Baranova, E.I.; Foscoli, M.; Dikic, A.D.; Filipova, S.; Fras, Z.; Bertomeu-Martínez, V.; Carlberg, B.; Burkard, T.; Sdiri, W.; Aydogdu, S.; Sirenko, Y.; Brady, A.; Weber, T.; Lazareva, I.; Backer, T.D.; Sokolovic, S.; Jelakovic, B.; Widimsky, J.; Viigimaa, M.; Pörsti, I.; Denolle, T.; Krämer, B.K.; Stergiou, G.S.; Parati, G.; Trušinskis, K.; Miglinas, M.; Gerdts, E.; Tykarski, A.; de Carvalho Rodrigues, M.; Dorobantu, M.; Chazova, I.; Lovic, D.; Filipova, S.; Brguljan, J.; Segura, J.; Gottsäter, A.; Pechère-Bertschi, A.; Erdine, S.; Sirenko, Y.; Brady, A. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J.,  2018, 39(33), 3021-3104.
 [http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]

[26]
Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, D.E.; Hansen, T.B.; Huikuri, H.V.; Johansson, I.; Jüni, P.; Lettino, M.; Marx, N.; Mellbin, L.G.; Östgren, C.J.; Rocca, B.; Roffi, M.; Sattar, N.; Seferović, P.M.; Sousa-Uva, M.; Valensi, P.; Wheeler, D.C.; Piepoli, M.F.; Birkeland, K.I.; Adamopoulos, S.; Ajjan, R.; Avogaro, A.; Baigent, C.; Brodmann, M.; Bueno, H.; Ceconi, C.; Chioncel, O.; Coats, A.; Collet, J-P.; Collins, P.; Cosyns, B.; Di Mario, C.; Fisher, M.; Fitzsimons, D.; Halvorsen, S.; Hansen, D.; Hoes, A.; Holt, R.I.G.; Home, P.; Katus, H.A.; Khunti, K.; Komajda, M.; Lambrinou, E.; Landmesser, U.; Lewis, B.S.; Linde, C.; Lorusso, R.; Mach, F.; Mueller, C.; Neumann, F-J.; Persson, F.; Petersen, S.E.; Petronio, A.S.; Richter, D.J.; Rosano, G.M.C.; Rossing, P.; Rydén, L.; Shlyakhto, E.; Simpson, I.A.; Touyz, R.M.; Wijns, W.; Wilhelm, M.; Williams, B.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, D.E.; Hansen, T.B.; Huikuri, H.V.; Johansson, I.; Jüni, P.; Lettino, M.; Marx, N.; Mellbin, L.G.; Östgren, C.J.; Rocca, B.; Roffi, M.; Sattar, N.; Seferović, P.M.; Sousa-Uva, M.; Valensi, P.; Wheeler, D.C.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J-P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.E.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.E.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Zelveian, P.H.; Scherr, D.; Jahangirov, T.; Lazareva, I.; Shivalkar, B.; Naser, N.; Gruev, I.; Milicic, D.; Petrou, P.M.; Linhart, A.; Hildebrandt, P.; Hasan-Ali, H.; Marandi, T.; Lehto, S.; Mansourati, J.; Kurashvili, R.; Siasos, G.; Lengyel, C.; Thrainsdottir, I.S.; Aronson, D.; Di Lenarda, A.; Raissova, A.; Ibrahimi, P.; Abilova, S.; Trusinskis, K.; Saade, G.; Benlamin, H.; Petrulioniene, Z.; Banu, C.; Magri, C.J.; David, L.; Boskovic, A.; Alami, M.; Liem, A.H.; Bosevski, M.; Svingen, G.F.T.; Janion, M.; Gavina, C.; Vinereanu, D.; Nedogoda, S.; Mancini, T.; Ilic, M.D.; Fabryova, L.; Fras, Z.; Jiménez-Navarro, M.F.; Norhammar, A.; Lehmann, R.; Mourali, M.S.; Ural, D.; Nesukay, E.; Chowdhury, T.A. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J.,  2020, 41(2), 255-323.
 [http://dx.doi.org/10.1093/eurheartj/ehz486] [PMID: 31497854]

[27]
Hageman, S.; Pennells, L.; Ojeda, F.; Kaptoge, S.; Kuulasmaa, K.; de Vries, T.; Xu, Z.; Kee, F.; Chung, R.; Wood, A.; McEvoy, J.W.; Veronesi, G.; Bolton, T.; Achenbach, S.; Aleksandrova, K.; Amiano, P.; Sebastian, D-S.; Amouyel, P.; Andersson, J.; Bakker, S.J.L.; Da Providencia Costa, R.B.; Beulens, J.W.J.; Blaha, M.; Bobak, M.; Boer, J.M.A.; Bonet, C.; Bonnet, F.; Boutron-Ruault, M-C.; Braaten, T.; Brenner, H.; Brunner, F.; Brunner, E.J.; Brunström, M.; Buring, J.; Butterworth, A.S.; Capkova, N.; Cesana, G.; Chrysohoou, C.; Colorado-Yohar, S.; Cook, N.R.; Cooper, C.; Dahm, C.C.; Davidson, K.; Dennison, E.; Di Castelnuovo, A.; Donfrancesco, C.; Dörr, M.; Doryńska, A.; Eliasson, M.; Engström, G.; Ferrari, P.; Ferrario, M.; Ford, I.; Fu, M.; Gansevoort, R.T.; Giampaoli, S.; Gillum, R.F.; Gómez de la Cámara, A.; Grassi, G.; Hansson, P-O.; Huculeci, R.; Hveem, K.; Iacoviello, L.; Ikram, M.K.; Jørgensen, T.; Joseph, B.; Jousilahti, P.; Wouter Jukema, J.; Kaaks, R.; Katzke, V.; Kavousi, M.; Kiechl, S.; Klotsche, J.; König, W.; Kronmal, R.A.; Kubinova, R.; Kucharska-Newton, A.; Läll, K.; Lehmann, N.; Leistner, D.; Linneberg, A.; Pablos, D.L.; Lorenz, T.; Lu, W.; Luksiene, D.; Lyngbakken, M.; Magnussen, C.; Malyutina, S.; Ibañez, A.M.; Masala, G.; Mathiesen, E.B.; Matsushita, K.; Meade, T.W.; Melander, O.; Meyer, H.E.; Moons, K.G.M.; Moreno-Iribas, C.; Muller, D.; Münzel, T.; Nikitin, Y.; Nordestgaard, B.G.; Omland, T.; Onland, C.; Overvad, K.; Packard, C.; Pająk, A.; Palmieri, L.; Panagiotakos, D.; Panico, S.; Perez-Cornago, A.; Peters, A.; Pietilä, A.; Pikhart, H.; Psaty, B.M.; Quarti-Trevano, F.; Garcia, J.R.Q.; Riboli, E.; Ridker, P.M.; Rodriguez, B.; Rodriguez-Barranco, M.; Rosengren, A.; Roussel, R.; Sacerdote, C.; Sans, S.; Sattar, N.; Schiborn, C.; Schmidt, B.; Schöttker, B.; Schulze, M.; Schwartz, J.E.; Selmer, R.M.; Shea, S.; Shipley, M.J.; Sieri, S.; Söderberg, S.; Sofat, R.; Tamosiunas, A.; Thorand, B.; Tillmann, T.; Tjønneland, A.; Tong, T.Y.N.; Trichopoulou, A.; Tumino, R.; Tunstall-Pedoe, H.; Tybjaerg-Hansen, A.; Tzoulaki, J.; van der Heijden, A.; van der Schouw, Y.T.; Verschuren, W.M.M.; Völzke, H.; Waldeyer, C.; Wareham, N.J.; Weiderpass, E.; Weidinger, F.; Wild, P.; Willeit, J.; Willeit, P.; Wilsgaard, T.; Woodward, M.; Zeller, T.; Zhang, D.; Zhou, B.; Dendale, P.; Ference, B.A.; Halle, M.; Timmis, A.; Vardas, P.; Danesh, J.; Graham, I.; Salomaa, V.; Visseren, F.; De Bacquer, D.; Blankenberg, S.; Dorresteijn, J.; Di Angelantonio, E. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J.,  2021, 42(25), 2439-2454.
 [http://dx.doi.org/10.1093/eurheartj/ehab309] [PMID: 34120177]

[28]
Corrigendum to: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J.,  2020, 41(44), 4255.
 [http://dx.doi.org/10.1093/eurheartj/ehz826] [PMID: 31837134]

[29]
Glossary.  Available from: https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm

[30]
Vriesendorp, P.A.; Schinkel, A.F.L.; Liebregts, M.; Theuns, D.A.M.J.; van Cleemput, J.; ten Cate, F.J.; Willems, R.; Michels, M. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ. Arrhythm. Electrophysiol.,  2015, 8(4), 829-835.
 [http://dx.doi.org/10.1161/CIRCEP.114.002553] [PMID: 25922410]

[31]
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement. Am. J. Respir. Crit. Care Med.,  2002, 166(1), 111-117.
 [http://dx.doi.org/10.1164/ajrccm.166.1.at1102] [PMID: 12091180]

[32]
Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; Lancellotti, P.; Muraru, D.; Picard, M.H.; Rietzschel, E.R.; Rudski, L.; Spencer, K.T.; Tsang, W.; Voigt, J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J. Am. Soc. Echocardiogr.,  2015, 28(1), 1-39.e14.
 [http://dx.doi.org/10.1016/j.echo.2014.10.003] [PMID: 25559473]

[33]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods,  2001, 25(4), 402-408.
 [http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]

[34]
Cerqueira, M.D.; Weissman, N.J.; Dilsizian, V.; Jacobs, A.K.; Kaul, S.; Laskey, W.K.; Pennell, D.J.; Rumberger, J.A.; Ryan, T.; Verani, M.S. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int. J. Cardiovasc. Imaging,  2002, 18(1), 539-542.
 [PMID: 12135124]

[35]
Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliansky, V.; Rosenwald, A.; Basson, M.A.; Licht, J.D.; Pena, J.T.R.; Rouhanifard, S.H.; Muckenthaler, M.U.; Tuschl, T.; Martin, G.R.; Bauersachs, J.; Engelhardt, S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature,  2008, 456(7224), 980-984.
 [http://dx.doi.org/10.1038/nature07511] [PMID: 19043405]

[36]
Derda, A.A.; Thum, S.; Lorenzen, J.M.; Bavendiek, U.; Heineke, J.; Keyser, B.; Stuhrmann, M.; Givens, R.C.; Kennel, P.J.; Christian, S.P.; Widder, J.D.; Bauersachs, J.; Thum, T. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int. J. Cardiol.,  2015, 196, 115-122.
 [http://dx.doi.org/10.1016/j.ijcard.2015.05.185] [PMID: 26086795]

[37]
van Rooij, E.; Sutherland, L.B.; Thatcher, J.E.; DiMaio, J.M.; Naseem, R.H.; Marshall, W.S.; Hill, J.A.; Olson, E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci.,  2008, 105(35), 13027-13032.
 [http://dx.doi.org/10.1073/pnas.0805038105] [PMID: 18723672]

[38]
Zhang, P.; Huang, A.; Ferruzzi, J.; Mecham, R.P.; Starcher, B.C.; Tellides, G.; Humphrey, J.D.; Giordano, F.J.; Niklason, L.E.; Sessa, W.C. Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels--brief report. Arterioscler. Thromb. Vasc. Biol.,  2012, 32(3), 756-759.
 [http://dx.doi.org/10.1161/ATVBAHA.111.238113] [PMID: 22095981]

[39]
Pekarsky, Y.; Santanam, U.; Cimmino, A.; Palamarchuk, A.; Efanov, A.; Maximov, V.; Volinia, S.; Alder, H.; Liu, C.G.; Rassenti, L.; Calin, G.A.; Hagan, J.P.; Kipps, T.; Croce, C.M. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res.,  2006, 66(24), 11590-11593.
 [http://dx.doi.org/10.1158/0008-5472.CAN-06-3613] [PMID: 17178851]

[40]
Mott, J.L.; Kobayashi, S.; Bronk, S.F.; Gores, G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene,  2007, 26(42), 6133-6140.
 [http://dx.doi.org/10.1038/sj.onc.1210436] [PMID: 17404574]

[41]
Wang, H.; Garzon, R.; Sun, H.; Ladner, K.J.; Singh, R.; Dahlman, J.; Cheng, A.; Hall, B.M.; Qualman, S.J.; Chandler, D.S.; Croce, C.M.; Guttridge, D.C. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell,  2008, 14(5), 369-381.
 [http://dx.doi.org/10.1016/j.ccr.2008.10.006] [PMID: 18977326]

[42]
Dai, Y.; Dai, D.; Mehta, J.L. MicroRNA-29, a mysterious regulator in myocardial fibrosis and circulating miR-29a as a biomarker. J. Am. Coll. Cardiol.,  2014, 64(20), 2181.
 [http://dx.doi.org/10.1016/j.jacc.2014.03.064] [PMID: 25457411]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0109298673286017240103073130	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X

Current Medicinal Chemistry

Expression of Circulating miR-21 and -29 and their Association with Myocardial Fibrosis in Hypertrophic Cardiomyopathy

Abstract Play Pause

Related Journals

Related Books

Abstract